U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C28H16ClF6N5O
Molecular Weight 587.903
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TRADIPITANT

SMILES

FC(F)(F)C1=CC(=CC(CN2N=NC(=C2C3=CC=NC=C3)C4=NC=CC=C4C(=O)C5=CC=CC=C5Cl)=C1)C(F)(F)F

InChI

InChIKey=CAVRKWRKTNINFF-UHFFFAOYSA-N
InChI=1S/C28H16ClF6N5O/c29-22-6-2-1-4-20(22)26(41)21-5-3-9-37-23(21)24-25(17-7-10-36-11-8-17)40(39-38-24)15-16-12-18(27(30,31)32)14-19(13-16)28(33,34)35/h1-14H,15H2

HIDE SMILES / InChI

Molecular Formula C28H16ClF6N5O
Molecular Weight 587.903
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Tradipitant is a neurokinin 1 receptor antagonist. The dose of 50 mg of tradipitant given orally for 4 weeks was not superior to placebo in reducing itch intensity in patients with atopic dermatitis. However, in a subsequent study, in which a higher dose (85 mg) was administered for 8 weeks, significant antipruritic effect compared with placebo was recorded. Tradipitant is in phase III clinical trial for the treatment of atopic dermatitis and gastroparesis. Vanda Pharmaceuticals plans a phase III trial in Motion Sickness in 2019.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
PubMed

PubMed

TitleDatePubMed
NK-1 Receptor Antagonists and Pruritus: Review of Current Literature.
2019 Sep
Patents
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:36:21 GMT 2025
Edited
by admin
on Mon Mar 31 18:36:21 GMT 2025
Record UNII
NY0COC51FI
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TRADIPITANT
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
tradipitant [INN]
Preferred Name English
Tradipitant [WHO-DD]
Common Name English
(2-(1-(3,5-BIS(TRIFLUOROMETHYL)BENZYL)-5-PYRIDIN-4-YL-1H-1,2,3-TRIAZOL-4-YL)PYRIDIN-3-YL)(2-CHLOROPHENYL)METHANONE
Systematic Name English
LY686017
Code English
TRADIPITANT [USAN]
Common Name English
METHANONE, (2-(1-((3,5-BIS(TRIFLUOROMETHYL)PHENYL)METHYL)-5-(4-PYRIDINYL)-1H-1,2,3-TRIAZOL-4-YL)-3-PYRIDINYL)(2-CHLOROPHENYL)-
Systematic Name English
LY-686017
Code English
VLY-686
Code English
Classification Tree Code System Code
NCI_THESAURUS C78284
Created by admin on Mon Mar 31 18:36:21 GMT 2025 , Edited by admin on Mon Mar 31 18:36:21 GMT 2025
Code System Code Type Description
SMS_ID
300000021772
Created by admin on Mon Mar 31 18:36:21 GMT 2025 , Edited by admin on Mon Mar 31 18:36:21 GMT 2025
PRIMARY
FDA UNII
NY0COC51FI
Created by admin on Mon Mar 31 18:36:21 GMT 2025 , Edited by admin on Mon Mar 31 18:36:21 GMT 2025
PRIMARY
USAN
CD-17
Created by admin on Mon Mar 31 18:36:21 GMT 2025 , Edited by admin on Mon Mar 31 18:36:21 GMT 2025
PRIMARY
EPA CompTox
DTXSID801045805
Created by admin on Mon Mar 31 18:36:21 GMT 2025 , Edited by admin on Mon Mar 31 18:36:21 GMT 2025
PRIMARY
WIKIPEDIA
Tradipitant
Created by admin on Mon Mar 31 18:36:21 GMT 2025 , Edited by admin on Mon Mar 31 18:36:21 GMT 2025
PRIMARY
DRUG BANK
DB12580
Created by admin on Mon Mar 31 18:36:21 GMT 2025 , Edited by admin on Mon Mar 31 18:36:21 GMT 2025
PRIMARY
PUBCHEM
9916461
Created by admin on Mon Mar 31 18:36:21 GMT 2025 , Edited by admin on Mon Mar 31 18:36:21 GMT 2025
PRIMARY
ChEMBL
CHEMBL3544984
Created by admin on Mon Mar 31 18:36:21 GMT 2025 , Edited by admin on Mon Mar 31 18:36:21 GMT 2025
PRIMARY
NCI_THESAURUS
C152707
Created by admin on Mon Mar 31 18:36:21 GMT 2025 , Edited by admin on Mon Mar 31 18:36:21 GMT 2025
PRIMARY
INN
9996
Created by admin on Mon Mar 31 18:36:21 GMT 2025 , Edited by admin on Mon Mar 31 18:36:21 GMT 2025
PRIMARY
CAS
622370-35-8
Created by admin on Mon Mar 31 18:36:21 GMT 2025 , Edited by admin on Mon Mar 31 18:36:21 GMT 2025
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
ANTAGONIST
IC50
Related Record Type Details
ACTIVE MOIETY
Entered into Phase II clinical trials for social anxiety disorder and alcoholism treatment. It was found ineffective against anxiety disorder. The results of the alcoholism treatment trial have not been published.